|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 13770 Noel Road |
Address2 | Suite 801889 |
City | Dallas |
State | TX |
Zip Code | 75280 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103626-12
|
||||||||
|
6. House ID# 428950001
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Molly Guthrie |
Date | 1/22/2023 6:33:21 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2617 - Consolidated Appropriations Act of 2023; related to funding for biomedical research, NBCCEDP, social determinants of health programs, consumer assistance programs, and related cancer services and report language related to genetic counseling and testing
H.R. 2617 - Consolidated Appropriations Act of 2023; FY2023 Defense appropriations related to funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer
Policies related to development of the Advanced Research Projects Agency for Health
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
|
Valerie |
Nauman |
|
|
|
Aracely |
Panameno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R. 4612/S. 2412 - Protecting Access to Lifesaving Screenings Act of 2021; a bill to make a series of changes relating to health insurance coverage of screening mammography
H.R. 5769/S. 1067 - Access to Breast Cancer Diagnosis Act; bill to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
H.R. 2163/S. 464 - Safe Step Act; bill to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes
H.R. 4385/S.3080 - Cancer Drug Parity Act; bill to require health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act; a bill to amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes
H.R. 7045/S. 3796 - Closing Health Coverage Gaps for Public Servants Act; a bill to eliminate the opt-out for nonfederal governmental health plans, including the opt-out for coverage for full mastectomy and reconstruction care
Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
Issues related to regulation of short-term limited duration plans
Implementation of the No Surprises Act
Implementation of the Inflation Reduction Act
Implementation of the Affordable Care Act
Policies regarding White House Cancer Moonshot implementation
Public and private insurance adjustments and other policy changes due to the COVID-19 emergency, including those impacting the immunocompromised populations
S. 942 - No Junk Plans Act; bill to overturn previous administration rule expanding non-comprehensive health insurance plans that dont have to provide healthcare coverage for people with pre-existing conditions
S. 1002 - Junk Plan Accountability and Disclosure Act; a bill which establishes requirements for certain noncomprehensive health insurance coverage and provides for additional outreach activities to increase enrollment in qualified health plans
Policies related to co-pay assistance programs
Comments in response to the RFI on Advanced Explanation of Benefits and Good Faith Estimate for Covered Individuals (CMS9900-NC)
Comments regarding Section 1557 Nondiscrimination in Health Programs and Activities (RIN 0945-AA17)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Treasury - Dept of, Labor - Dept of (DOL), Centers For Medicare and Medicaid Services (CMS), Internal Revenue Service (IRS), Office of Science & Technology Policy (OSTP), Office of Personnel Management (OPM)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
|
Valerie |
Nauman |
|
|
|
Aracely |
Panameno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance.
H.R. 1946/S. 1873 -Medicare Multi-Cancer Early Detections Screening and Coverage Act; bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening test
H.R. 3183/S. 1312 - Metastatic Breast Cancer Access to Care Act; bill to exempt individuals with metastatic breast cancer from certain waiting periods for disability insurance benefits under the Old-Age, Survivors, and Disability Insurance program and related Medicare coverage
H.R. 2903/S. 1512 - CONNECT for Health Act; a bill to expand the use of telehealth and remote patient monitoring services in Medicare
H.R. 3087/S. 2051 - Breast Cancer Patient Equity Act; a bill to provide for Medicare coverage of custom fabricated breast prostheses
H.R. 3630/S. 1315 - Lymphedema Treatment Act; bill to include certain lymphedema compression treatment items as covered durable medical equipment under Medicare following the surgical removal of the breast (i.e., a mastectomy), including replacements of such prostheses
H.R. 4110 - Reducing Hereditary Cancer Act of 2021; a bill to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer
H.R. 4612/S. 2412 - Protecting Access to Lifesaving Screenings Act of 2021; a bill to make a series of changes relating to health insurance coverage of screening mammography including preserving Medicare coverage for screening mammography, without a requirement for coinsurance, and expands the definition of screening mammography to include any digital modality of such a procedure
S. 2327 - Seniors Prescription Drug Relief Act; a bill to amend title XVIII of the Social Security Act to provide for a Medicare part D modernization redesign and to establish a monthly out-of-pocket cost sharing maximum for enrollees who incur a significant portion of costs towards the annual out-of-pocket threshold under Medicare part D
H.R. 3173/S. 3018 - Improving Seniors Timely Access to Care Act; a bill which establishes several requirements and standards relating to prior authorization processes under Medicare Advantage (MA) plans
H.R. 7213, Equitable Community Access to Pharmacist Services Act; a bill to provide pharmacy reimbursement for COVID-19-related and future emergency services.
H.R. 9505, Find It Early Act; a bill to provide for health coverage with no cost-sharing additional breast screenings for certain individuals
Comments regarding the temporary increase in federal medical assistance percentage (FMAP) in response to the COVID-19 Public Health Emergency (PHE) (CMS-9912-N)
Comments in response to the Medicaid Eligibility and Enrollment NPRM (CMS-2421-P)
Comments in response to the RFI regarding National Directory of Healthcare Providers & Services (CMS-0058-NC)
Comments in response to the RFI regarding accessing healthcare and related challenges, understanding provider experiences, advancing health equity, and assessing the impact of waivers and flexibilities provided in response to the COVID-19 Public Health Emergency (PHE)
Issues related to the upcoming Notice on Benefit and Payment Parameters for FY2024
Medicare coverage policy for drugs and drug pricing
Medicare coverage policy for breast cancer treatments and services
Proposed waivers under Sections 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid
Policies related to funding, state incentives, and federal efforts for for Medicaid expansion
Coverage for telemedicine in Medicare
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Treasury - Dept of, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
|
Valerie |
Nauman |
|
|
|
Aracely |
Panameno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R. 2617 - Consolidated Appropriations Act of 2023; FY 2023 Funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer
H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023; a bill to authorize Department of Defense activities and programs for FY 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
|
Valerie |
Nauman |
|
|
|
Aracely |
Panameno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 379/S. 104 - Improving Social Determinants of Health Act; bill to require the Centers for Disease Control and Prevention (CDC) to establish a program to improve health outcomes and reduce health inequities by, for example, coordinating activities across the CDC. As part of the program, the CDC must award grants to eligible organizations to build capacity to address social determinants of health.
H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance.
H.R. 5030/S.2706 - DIVERSE Trials Act; A bill to require FDA to issue guidance on decentralized clinical trials to promote meaningful demographic/geographic diversity in patient engagement, expand reporting by laboratories that test for and diagnose COVID-19, and require a study on data collection and data sharing during public health emergencies
H.R. 6000 - Cures 2.0 Act; a comprehensive healthcare and biomedical research bill
H.R. 4794/S. 2533 - Making Advances in Mammography and Medical Options for Veterans Act; a bill to improve mammography services furnished by the Department of Veterans Affairs
H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021; a bill to expand eligibility for Veterans Health Administration mammography screenings to veterans who served in certain locations during specified periods, including those who were exposed to toxic substances at such locations
H.R. 6584 - Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes.
S. 3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; a bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics.
H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.
H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027
S. 4260 - Palliative Care and Hospice Education and Training Act; a bill to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools, social work schools, and other programs, including physician assistant education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative medicine.
H.R. 7667/S. 4348 - Food and Drug Amendments of 2022; a bill to reauthorize Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.
H.R. 9565/S. 5295- Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivors background, or forthcoming survivorship needs, and for other purposes.
Policies related to telehealth
Policies to increase clinical trial diversity and access for underrepresented populations
Policies related to genetic counseling and testing
Policies related to cancer survivorship
Policies related to PBM and drug cost transparency
Policies related to the reauthorization of FDA User Fee Agreements
Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017
Policies related to the implementation of the Mammography Quality Standards Act
Policies related to administration actions necessary in breast imaging and breast cancer diagnosis
Comments regarding a request for information on establishing a National Directory of Healthcare Providers and Services
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
|
Valerie |
Nauman |
|
|
|
Aracely |
Panameno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |